Clinical trials and research studies are vital in the mission to find better treatments and cures for Nephrotic Syndrome. When you participate in a clinical trial, not only can you gain access to cutting-edge treatment options and expert care, but patient participation in clinical trials is the only way that new treatments will become possible.
Nephrotic Syndrome patients have a great reason to feel hope, because today, there are more clinical trials for Nephrotic Syndrome conditions than ever before. We are working hard on a new website that will help you navigate the many trial options that are available to you today. Please stay tuned for more information on this new website, which we are launching on February 19, 2019. We encourage you to give it a try—you may be amazed at all the trials that you are eligible for!
In the meantime, you can find a full list of clinical trials below. You should ask your doctor about any trials you’re interested in. You can also learn more about the benefits and risks of participating in Clinical Research here.
Still want more information about clinical trials? Check out these debunked trial myths.
Ongoing Clinical Trials in The US
DISCOVERY –Phase 2 Clinical Trial of APL-2 Therapy in Patients with IgAN, LN, Primary MN, and C3G.
- DISCOVERY is a Phase 2 study testing the safety and biologic activity of APL-2 therapy. Patients that enroll in the study will participate for 1 year, which includes a screening period, 16 weeks of treatment, and 24 weeks of follow-up appointments.
- Learn more about this clinical trial
FIRSTx – A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
- FIRSTx is a Phase 2 study testing the safety and effectiveness of an investigational drug called CXA-10 designed to treat FSGS without steroids. This study will see if CXA-10 can reduce proteinuria while maintaining stable kidney function in people with FSGS.
- Learn more about this clinical trial
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
- The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis.
- Learn more about this clinical trial
PHOENIX- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
- PHOENIX is a multi-center, open-label Phase 2 trial evaluating the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD). Approximately 100 patients will enroll in the trial at research centers across the United States.
- Learn more about this clinical trial
Study of Sparsentan in FSGS (DUPLEX)
- The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor agonist. The active control is irbesartan. This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 150 study centers, globally.
- Learn more about this clinical trial
The PODO Trial: Trial to Evaluate PF-06730512 in Adults with FSGS
- The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS.
- Learn more about this clinical trial
Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS (The PODOCYTE Study)
- The purpose of the study is to determine whether H.P. Acthar® Gel (repository corticotropin injection) is helpful for adult patients with FSGS who still have an abnormal amount of protein in their urine, despite prior treatment.
- Learn more about this clinical trial
Evaluation of CCX140 in Focal Segmental Glomerulosclerosis with and without Nephrotic Syndrome Disease (LUMINA studies)
- The aim of this study is to evaluate the effect of treatment with CCX140-B in patients with focal segmental glomerulosclerosis on urinary protein excretion, which will be measured by changes in UPCR.
- Learn more about this clinical trial
Click Here for a Full List of Ongoing Clinical Trials
Use the trial finder below to find more trials that you may be eligible for
NephCure does not endorse participation in any specific clinical study. Individuals should consult with their physician or health care provider to discuss the benefits & risk of enrolling in a clinical trial.
Follow Us